The abstract is read at the publisher; the summary is JClub's.
GLP-1 receptor agonists are essential after their addition to the WHO Model List, but access remains inadequate, especially in low- and middle-income countries.
- Why it matters: The gap is that listing essential medicines does not ensure equitable availability, leaving low- and middle-income countries without reliable access to GLP-1 receptor agonists.
- What they did: This Perspective outlines actions to improve accessibility of GLP-1 receptor agonists, focusing on implementation needs following their inclusion on the WHO Model List of Essential Medicines.
- The result: Addressing these actions is implied to be necessary to translate essential status into real-world access, particularly in low- and middle-income countries.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.